Market Overview

Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

Share:
Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE).

The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes.

"We are excited to get underway with another clinical study and very pleased with our continued cooperation and collaboration with the FDA," said CEO Stephen From. "Pending the success of our PE agenda, we believe our unique OBG eye drop will be the first approved eye drop in the U.S. for the treatment of PE. Following the data readout of this pilot study, which we expect by year-end, we will re-convene with the FDA to establish the most suitable endpoint to use in a pivotal study."

Eyegate Pharmaceuticals shares were trading up 12.5% at 25 cents in Monday’s pre-market session. The stock has a 52-week high of 64 cents and a 52-week low of 20 cents.

Related Links:

GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Posted-In: dry eye disease dry eyesNews Penny Stocks FDA Markets Best of Benzinga

 

Related Articles (EYEG)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

How CVS Wants To Be Less Like A Pharmacy Chain And More Like Amazon

6 Utilities Stocks Moving In Today's Pre-Market Session